CAMPRAL

This brand name is authorized in Australia, Austria, Canada, Estonia, Ireland, Netherlands, Poland, Spain, Turkey, UK.

Active ingredients

The drug CAMPRAL contains one active pharmaceutical ingredient (API):

1	Acamprosate UNII 59375N1D0U - ACAMPROSATE CALCIUM
	Acamprosate has a chemical structure similar to that of amino acid neuromediators, such as taurine or gamma-amino-butyric acid (GABA), including an acetylation to permit passage across the blood brain barrier. Acamprosate may act by stimulating GABAergic inhibitory neurotransmission and antagonising excitatory aminoacids, particularly glutamate. It is indicated as therapy to maintain abstinence in alcohol-dependent patients.
	Read more about Acamprosate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CAMPRAL Enterocoated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07BB03	Acamprosate	N Nervous system → N07 Other nervous system drugs → N07B Drugs used in addictive disorders → N07BB Drugs used in alcohol dependence
Discover more medicines within N07BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8357W
CA	Health Products and Food Branch	02293269
EE	Ravimiamet	1700187, 1805138, 1809424, 1854064
ES	Centro de información online de medicamentos de la AEMPS	61201
GB	Medicines & Healthcare Products Regulatory Agency	19159
IE	Health Products Regulatory Authority	15931
NL	Z-Index G-Standaard, PRK	44113
PL	Rejestru Produktów Leczniczych	100082236
TR	İlaç ve Tıbbi Cihaz Kurumu	8699808040015